NTRK2 Fusion

CI-VAR-00001300Explore in graph →CIViC 3158

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 6 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Anaplastic Ependymoma1
KANK1::NTRK2 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID10360 An MRI in a previously healthy 6-year-old boy now presenting with neurologic abnormalities and seizures revealed a mass obstructing the foramen of Monro and diffuse leptomeningeal dissemination. The p… (full text at CIViC) PMID 34651095 · Mangum et al., 2021 · Open in CIViC	civic
Brain Glioblastoma1
KANK1::NTRK2 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	1	accepted	EID10896 From a retrospective review of 38,095 tumor samples from 33,997 patients that underwent fusion screening at Memorial Sloan Kettering Cancer Center, 87 tumors were found to be positive for an NTRK1, NT… (full text at CIViC) PMID 31375766 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Ganglioneuroblastoma1
KANK1::NTRK2 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	1	accepted	EID11854 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (7 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic

Glioblastoma1
KANK1::NTRK2 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID10361 An MRI of 26-year-old man presenting with motor weakness and language difficultly revealed a lesion in the left frontal lobe that extended across the corpus callosum. Histologic analysis of the biopsy… (full text at CIViC) PMID 34041811 · Shepherd et al., 2021 · Open in CIViC	civic

Pilocytic Astrocytoma1
KANK1::NTRK2 Fusion	(diagnostic)	Diagnostic	C	Supports Positive	2	accepted	EID8653 A case report showing a two-year-old girl with an unusual pilocytic astrocytoma (PA) with both classic- and anaplastic- appearing tumors. A custom NGS panel identified a novel KANK1-NTRK2 fusion in bo… (full text at CIViC) PMID 29804288 · López et al., 2019 · Open in CIViC	civic

Sarcoma1
KANK1::NTRK2 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	accepted	EID10362 In a further investigation of non-traditional sarcoma cases, a 41-year-old man was thought to have a malignant peripheral nerve sheath tumor (MPNST) in the neck and spinal cord, but large rhabdoid/epi… (full text at CIViC) PMID 34464935 · Chen et al., 2021 · Open in CIViC	civic